{
    "hands_on_practices": [
        {
            "introduction": "Understanding the frequency of a genetic disease within a population is a cornerstone of medical genetics. The Hardy-Weinberg equilibrium principle provides a powerful mathematical model to connect the incidence of an autosomal recessive disorder, like many Glycogen Storage Diseases, to the frequency of the pathogenic allele and the prevalence of asymptomatic carriers. This practice exercise will guide you through calculating the carrier frequency for a GSD, a crucial skill for interpreting population screening data and assessing baseline genetic risk.",
            "id": "5042470",
            "problem": "A particular glycogen storage disease (GSD) is inherited as an autosomal recessive trait caused by biallelic pathogenic variants at a single locus with two alleles, wild-type $A$ and pathogenic $a$. Consider a large, randomly mating population in Hardy–Weinberg equilibrium (HWE), with no selection, mutation, migration, or genetic drift, and complete penetrance. Let the allele frequencies of $A$ and $a$ be $p$ and $q$, respectively, with $p+q=1$. The observed incidence of clinically affected individuals (genotype $aa$) in this population is $q^{2} = \\frac{1}{100{,}000}$.\n\nStarting from the definitions of allele and genotype frequencies under HWE, derive the expected carrier (heterozygous $Aa$) frequency in terms of $q$, and then compute its numerical value using the given incidence. Express your final answer as a decimal fraction, rounded to four significant figures.",
            "solution": "The problem statement is evaluated as valid. It is scientifically grounded in the principles of population genetics, specifically the Hardy–Weinberg equilibrium (HWE). The problem is well-posed, with all necessary data and definitions provided to derive a unique and meaningful solution. It is free of ambiguity, contradiction, and subjective claims.\n\nThe problem addresses an autosomal recessive disorder determined by a single gene with two alleles: a wild-type allele $A$ with frequency $p$ and a pathogenic allele $a$ with frequency $q$. In a population under HWE, the relationship between these allele frequencies is $p + q = 1$.\n\nThe frequencies of the three genotypes—homozygous wild-type ($AA$), heterozygous ($Aa$), and homozygous pathogenic ($aa$)—are described by the terms of the binomial expansion of $(p+q)^2$:\n- Frequency of genotype $AA$ is $p^2$.\n- Frequency of genotype $Aa$ is $2pq$.\n- Frequency of genotype $aa$ is $q^2$.\n\nThe sum of these genotype frequencies must equal $1$: $p^2 + 2pq + q^2 = (p+q)^2 = 1^2 = 1$.\n\nCarriers of the disease are heterozygous individuals with the genotype $Aa$. Therefore, the carrier frequency is the frequency of the $Aa$ genotype, which is $2pq$.\n\nThe problem requires the derivation of this carrier frequency in terms of the allele frequency $q$. We use the relation $p = 1 - q$ and substitute it into the expression for the carrier frequency:\n$$\n\\text{Carrier Frequency} = 2pq = 2(1-q)q = 2q - 2q^2\n$$\nThis is the required derived expression.\n\nNext, we are asked to compute the numerical value of the carrier frequency. The problem provides the incidence of clinically affected individuals (genotype $aa$) as:\n$$\nq^2 = \\frac{1}{100,000} = 1 \\times 10^{-5} = 0.00001\n$$\nFrom this, we can find the frequency of the pathogenic allele, $q$, by taking the square root:\n$$\nq = \\sqrt{q^2} = \\sqrt{1 \\times 10^{-5}} = \\sqrt{0.00001}\n$$\nNow, we substitute the values of $q$ and $q^2$ into the derived expression for the carrier frequency:\n$$\n\\text{Carrier Frequency} = 2q - 2q^2 = 2\\sqrt{0.00001} - 2(0.00001)\n$$\nPerforming the numerical calculation:\n$$\nq = \\sqrt{0.00001} \\approx 0.00316227766\n$$\nThe carrier frequency is calculated as:\n$$\n\\text{Carrier Frequency} \\approx 2(0.00316227766) - 2(0.00001) = 0.00632455532 - 0.00002 = 0.00630455532\n$$\nThe problem specifies that the final answer should be expressed as a decimal fraction rounded to four significant figures. The calculated value is approximately $0.00630455532$. The first significant figure is $6$, the second is $3$, the third is $0$, and the fourth is $4$. The fifth significant figure is $5$, which requires rounding up the fourth digit.\n$$\n0.00630455532 \\approx 0.006305\n$$\nThus, the expected carrier frequency is $0.006305$.",
            "answer": "$$\\boxed{0.006305}$$"
        },
        {
            "introduction": "While population statistics provide a broad overview, genetic counseling for GSDs often focuses on the specific risks within a single family. This requires a firm grasp of Mendelian inheritance patterns. This next problem shifts our focus to a specific case involving an X-linked form of GSD, demonstrating how to calculate the precise recurrence risk for future children based on the parents' genetic status. Mastering this type of risk assessment is fundamental to providing accurate and compassionate guidance to families affected by inherited conditions.",
            "id": "5042486",
            "problem": "A couple seeks counseling about Glycogen Storage Disease (GSD) IX due to a known pathogenic variant in the phosphorylase kinase alpha $2$ (PHKA2) gene in the mother. PHKA2-related GSD IX is inherited in an X-linked recessive (XLR) manner. The mother is a confirmed heterozygous carrier of a pathogenic PHKA2 variant, and the father is clinically unaffected and has tested negative for PHKA2 pathogenic variants. Assume the following foundational principles:\n- Mendelian segregation applies, with equal segregation of alleles during gametogenesis.\n- Sex determination follows the standard model in humans: sons inherit the $Y$ chromosome from the father and the single maternal $X$, whereas daughters inherit one $X$ chromosome from each parent.\n- The sex ratio at birth is $1:1$.\n- Penetrance is complete in hemizygous males with the pathogenic PHKA2 variant; heterozygous females are not considered clinically affected for the purpose of this calculation.\n- The probability of de novo mutation and germline mosaicism is negligible.\n\nUsing these principles, derive from first principles the probability that a future son will be affected with PHKA2-related GSD IX and the probability that a future daughter will be affected. Express each probability as an exact fraction (no rounding). Report your final result as a row matrix with entries in the order $\\big(P(\\text{affected son}),\\,P(\\text{affected daughter})\\big)$.",
            "solution": "We begin from Mendelian and chromosomal principles. For an X-linked gene such as PHKA2, males are hemizygous ($XY$) and possess a single $X$ chromosome inherited from the mother, while females are typically heterozygous or homozygous at X-linked loci as they inherit two $X$ chromosomes (one from each parent).\n\nGiven:\n- The mother is heterozygous for a pathogenic PHKA2 variant, so her two $X$ chromosomes can be denoted as $X^{\\ast}$ (pathogenic) and $X$ (non-pathogenic).\n- The father is unaffected and has a normal $X$ chromosome and a $Y$ chromosome, denoted $X$ and $Y$.\n\nFoundational rules:\n- By Mendel’s first law (law of segregation), the mother transmits $X^{\\ast}$ with probability $\\frac{1}{2}$ and $X$ with probability $\\frac{1}{2}$ to each child.\n- For sons, the paternal contribution is necessarily $Y$, and for daughters, the paternal contribution is necessarily $X$.\n- The sex ratio is $1:1$, but because the problem asks for the probability conditional on the child being a son versus a daughter, we compute conditional probabilities for each sex.\n\nCompute the risk for a son:\n- A son inherits $Y$ from the father and one $X$ from the mother. The probability the son inherits $X^{\\ast}$ from the mother is $\\frac{1}{2}$.\n- A male who inherits $X^{\\ast}$ is hemizygous for the pathogenic variant and, under the assumption of complete penetrance in hemizygous males, will be affected.\n- Therefore, the probability that a future son is affected is\n$$\nP(\\text{affected son}) \\;=\\; \\frac{1}{2}.\n$$\n\nCompute the risk for a daughter:\n- A daughter inherits the father’s normal $X$ and one maternal $X$. With probability $\\frac{1}{2}$ she inherits $X^{\\ast}$ and becomes a heterozygous carrier ($X^{\\ast}X$), and with probability $\\frac{1}{2}$ she inherits the maternal normal $X$ and is $XX$.\n- Under X-linked recessive inheritance with an unaffected father and the stated assumption that heterozygous females are not considered clinically affected for this calculation, daughters will not be affected because they always receive a normal $X$ from the unaffected father.\n- Therefore, the probability that a future daughter is affected is\n$$\nP(\\text{affected daughter}) \\;=\\; 0.\n$$\n\nThus, the requested row matrix in the specified order $\\big(P(\\text{affected son}),\\,P(\\text{affected daughter})\\big)$ is\n$$\n\\begin{pmatrix}\n\\frac{1}{2} & 0\n\\end{pmatrix}.\n$$",
            "answer": "$$\\boxed{\\begin{pmatrix}\\frac{1}{2} & 0\\end{pmatrix}}$$"
        },
        {
            "introduction": "Moving from inheritance patterns to the molecular level helps us understand why a particular genetic makeup results in disease. In many autosomal recessive disorders, individuals are affected because they inherit two different faulty versions of a gene, a state known as compound heterozygosity. This exercise provides a quantitative model to predict the total enzyme function in a patient with two distinct pathogenic alleles, linking specific molecular defects to the overall clinical phenotype. This practice is key to appreciating the complex relationship between genotype and disease severity in GSDs.",
            "id": "5042459",
            "problem": "An autosomal recessive glycogen storage disease (GSD) caused by deficiency of acid alpha-glucosidase (GAA) is diagnosed in a patient who is a compound heterozygote for two missense variants in the GAA gene. Acid alpha-glucosidase is a lysosomal hydrolase that functions as a monomer. Assume the following widely accepted biological foundations: the Central Dogma of Molecular Biology (deoxyribonucleic acid to ribonucleic acid to protein), that each allele in a diploid cell produces protein proportional to its messenger ribonucleic acid abundance and translational efficiency, and that at saturating substrate the maximal velocity of an enzyme is proportional to the catalytic turnover constant and the enzyme concentration. For mixtures of enzyme molecules that differ in catalytic turnover, total maximal velocity reflects the sum of contributions of each subpopulation.\n\nVariant $1$ produces enzyme molecules with a catalytic turnover that is a fraction $0.30$ of normal and has steady-state expression at a fraction $0.80$ of a normal allele (due to partially reduced folding efficiency). Variant $2$ produces enzyme molecules with a catalytic turnover that is a fraction $0.10$ of normal but has expression comparable to a normal allele, which we take as fraction $1.00$. There is no dominant-negative interaction, no obligate oligomerization, and substrate availability is not rate-limiting.\n\nNormalize total maximal velocity for a wild-type homozygote (two normal alleles) to $1.00$. Under these assumptions, which option best represents the expected fraction of overall enzyme function in this compound heterozygote relative to wild-type, together with the correct rationale for how two missense variants combine to determine the total activity?\n\nA. $0.20$, obtained by averaging the residual catalytic turnovers of the two variants and assuming expression differences are negligible.\n\nB. $0.17$, obtained by summing each allele’s contribution based on its expression fraction multiplied by its residual catalytic turnover, and normalizing to the wild-type total.\n\nC. $0.34$, obtained by summing the residual catalytic turnovers without normalization to the wild-type total.\n\nD. $0.10$, determined by the lower of the two residual activities because the less active allele limits overall flux in autosomal recessive disease.\n\nE. $0.03$, obtained by multiplying the two residual catalytic turnovers to reflect the need for both alleles to be functional simultaneously for monomeric enzyme activity.",
            "solution": "The problem is scientifically sound, well-posed, and relies on established principles of enzyme kinetics and molecular genetics to model the genotype-phenotype correlation in a compound heterozygote. All necessary data are provided, and the assumptions (monomeric enzyme, no dominant-negative interaction) are clearly stated.\n\nThe solution proceeds by calculating the total enzymatic activity in a compound heterozygote and normalizing it to the activity of a wild-type homozygote.\n\n1.  **Establish a Baseline for Wild-Type (WT) Activity:** A WT homozygote possesses two normal alleles. The enzymatic contribution of a single WT allele can be defined as the product of its relative expression level (fraction $1.00$) and its relative catalytic turnover (fraction $1.00$).\n    - Contribution of one WT allele = $1.00 (\\text{expression}) \\times 1.00 (\\text{turnover}) = 1.0$ arbitrary unit of activity.\n    - A WT homozygote has two such alleles, so the total WT activity is $1.0 + 1.0 = 2.0$ arbitrary units. This total is the reference value, which is normalized to $1.00$.\n\n2.  **Calculate the Patient's Total Activity:** The patient is a compound heterozygote. Since the enzyme is a monomer and there are no interactions, the total activity is the simple sum of the contributions from each of the two different pathogenic alleles.\n    - Contribution from Variant 1 = (Relative Expression) $\\times$ (Relative Turnover) = $0.80 \\times 0.30 = 0.24$ arbitrary units.\n    - Contribution from Variant 2 = (Relative Expression) $\\times$ (Relative Turnover) = $1.00 \\times 0.10 = 0.10$ arbitrary units.\n    - Patient's total activity = Contribution from Variant 1 + Contribution from Variant 2 = $0.24 + 0.10 = 0.34$ arbitrary units.\n\n3.  **Normalize Patient's Activity to Wild-Type:** The problem asks for the fraction of overall enzyme function relative to the wild-type homozygote.\n    - Relative Activity Fraction = $\\frac{\\text{Patient's Total Activity}}{\\text{Wild-Type Total Activity}} = \\frac{0.34 \\text{ units}}{2.0 \\text{ units}} = 0.17$.\n    - The expected fraction of enzyme function is $0.17$, or $17\\%$ of normal.\n\n4.  **Evaluate the Options:**\n    -   **A. 0.20:** This is the simple average of the catalytic turnovers: $(0.30 + 0.10) / 2 = 0.20$. This calculation incorrectly ignores the different expression levels of the two alleles and uses an inappropriate averaging method. Verdict: **Incorrect**.\n    -   **B. 0.17:** This is derived by summing the contribution of each allele (product of expression and turnover) and normalizing to the total WT activity from two alleles: $((0.80 \\times 0.30) + (1.00 \\times 0.10)) / 2 = 0.17$. This method is biochemically correct based on the problem's premises. Verdict: **Correct**.\n    -   **C. 0.34:** This is the unnormalized sum of the patient's allelic activities ($0.24 + 0.10 = 0.34$). It fails to normalize against the total activity of a WT homozygote (which has *two* functional alleles), effectively comparing the patient's activity to only half the normal level. Verdict: **Incorrect**.\n    -   **D. 0.10:** This assumes the less active allele is the sole determinant of the phenotype. This is biologically incorrect for monomeric enzymes where both alleles contribute to the total pool of enzyme molecules. Verdict: **Incorrect**.\n    -   **E. 0.03:** This is the product of the two catalytic turnovers ($0.30 \\times 0.10 = 0.03$). This would imply a functional relationship, such as needing both variant proteins to form a complex, which is contrary to the problem stating the enzyme is a monomer. Verdict: **Incorrect**.",
            "answer": "$$\\boxed{B}$$"
        }
    ]
}